- Joined
- Apr 3, 2019
- Messages
- 65
- Reaction score
- 90
Hi y'all, potentially very naive medical student question incoming:
Background is that I'm from California and worked at a residential mh facility/community psychiatry program for a little over 3 years before starting medical school. Meth addiction is/was devastating to this population and posed tremendous barriers to recovery. Treating SMI within the context of active meth addiction felt essentially,, farcical and, anecdotally, I saw that meth addiction had much poorer outcomes in rehab.
I recently learned that TMS is emerging as a promising treatment for all sorts of addictions, including meth. My question is: since treatment outcomes with meth addiction are so bad, what factors would stop a physician from just ~trying out~ a promising treatment? What separates off-label use of bupropion (something regularly covered by insurance) from off-label use of TMS?
I'm currently in a fellowship on SUD treatment that is based in PA (so primary lens of OUD). When I ask about meth I feel like the answers are mostly ¯\_(ツ)_/¯ because it's less prevalent there than on the west coast. Meth has been so destructive to communities I care about and I wish it were prioritized more in addiction medicine. Thanks in advance for indulging me with any replies to this thread.
Background is that I'm from California and worked at a residential mh facility/community psychiatry program for a little over 3 years before starting medical school. Meth addiction is/was devastating to this population and posed tremendous barriers to recovery. Treating SMI within the context of active meth addiction felt essentially,, farcical and, anecdotally, I saw that meth addiction had much poorer outcomes in rehab.
I recently learned that TMS is emerging as a promising treatment for all sorts of addictions, including meth. My question is: since treatment outcomes with meth addiction are so bad, what factors would stop a physician from just ~trying out~ a promising treatment? What separates off-label use of bupropion (something regularly covered by insurance) from off-label use of TMS?
I'm currently in a fellowship on SUD treatment that is based in PA (so primary lens of OUD). When I ask about meth I feel like the answers are mostly ¯\_(ツ)_/¯ because it's less prevalent there than on the west coast. Meth has been so destructive to communities I care about and I wish it were prioritized more in addiction medicine. Thanks in advance for indulging me with any replies to this thread.